share_log

复星医药(02196.HK):复宏汉霖获药品临床试验批准

Fosun Pharmaceutical (02196.HK): Fuhong Hanlin was approved for drug clinical trials

Gelonghui Finance ·  Apr 17 05:45

Gelonghui, April 17 | Fosun Pharmaceutical (02196.HK) announced that the company's holding subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its holding subsidiary (hereinafter collectively referred to as “Fuhong Hanlin”) recently received approval from the State Drug Administration to conduct clinical trials with HLX53 (i.e. anti-Tigit FC fusion protein) in combination with Hans form (i.e. slulizumab injection) and Hanbetai (i.e. bevacizumab injection) for first-line treatment of locally advanced or metastatic hepatocellular carcinoma (HCC). Fu Hong Hanlin plans to conduct phase II clinical trials of this treatment plan in China (excluding Hong Kong, Macao and Taiwan regions, same below) after conditions are met.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment